대사증후군과 산화스트레스, 항산화제

키워드

참고문헌 (84)

1. 박혜순, "한국인에서의 대사증후군의 역학", 대한비만학회지, (11), pp.203~211 (2002)
2. 권혁상, "한국 성인에서의 NCEP-ATP III 기준을 적용한 대사증후군 유병률과 임상적 특징", 대한내과학회지, 68(4), pp.359~368 (2005), 대한내과학회
3. 최영호, "춘천 지역 중년 및 노인에서의 대사증후군의 유병률과 관련위험요인: 한림노년 연구.", 가정의학회지, 27(3), pp.190~200 (2006)
4. Maddux BA,, "Protection against oxidative stress-induced insulin resistance in rat L6 muscle cells by mircomolar concentrations of alpha-lipoic acid", Diabetes, (50), pp.404~410 (2001)
5. Taniyama Y, "Reactive oxygen species in the vasculature: molecular and cellular mechanisms", Hypertension, (42), pp.1075~1081 (2003)
6. Lee KU, "Oxidative stress markers in Korean subjects with insulin resistance syndrome.", Diabetes Res Clin Pract, 54(2), pp.S29~S33 (2001)
7. Furukawa S, "Increased oxidative stress in obesity and impact on metabolic syndrome", J Clin Invest, (114), pp.1752~1761 (2004)
8. Facchini FS, "Hyperinsulinemia: the missing link among oxidative stress and age- related diseases?", Free Radic Biol Med, (29), pp.1302~1306 (2000)
9. Weisberg SP, "Obesity is associated with macrophage accumulation in adipose tissue", J Clin Inves, (112), pp.1796~1808 (2003)
10. Fruhbeck G, "The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation.", Am J Physiol Endocrinol Metab, (280), pp.E827~E847 (2001)
11. Inoguchi T, "NAD(P)H oxidase activation: a potential target mechanism for diabetic vascular complications, progressive beta-cell dysfunction and metabolic syndrome.", Curr Drug Targets, (6), pp.495~501 (2005)
12. Lemieux I, "Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity.", Arterioscler Thromb Vasc Biol, (21), pp.961~967 (2001)
13. Ridker PM, "High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.", Circulation, (103), pp.1813~1818 (2001)
14. Rosenson RS, "Statin use in acute coronary syndromes: cellular mechanism and clinical evidence.", Curr Opin Lipidol, (13), pp.625~630 (2002)
15. Hansen LL, "Insulin signaling is inhibited by micromolar concentrations of H(2)O(2): evidence for a role of H(2)O(2) in tumor necrosis factor alpha-mediated insulin resistance.", J Biol Chem, (274), pp.5078~5084 (1999)
16. Rudich A, "Oxidant stress reduces insulin responsiveness in 3T3-L1 adipocytes.", Am J Physiol, 272(5 Pt 1), pp.E935~E940 (1997)
17. Hotamisligil GS, "Adipose expression of tumor necrosis factor-α: direct role in obesity linked insulin resistance.", Science, (259), pp.87~91 (1993)
18. Zinman B, "Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus.", J Clin Endocrinol Metab, (84), pp.272~278 (1999)
19. 박상수, "혈청 아디포넥틴 농도와 대사증후군 발병의 연관성", 대한내분비학회지, 19(5), pp.492~500 (2004)
20. 감성재, "폐경 전 비만여성에서 내장지방량에 따른 혈중 아디포넥틴 농도와 대사증후군 관련인자와의 상관관계.", 대한내과학회지, 66(3), pp.259~266 (2004)
21. Matsuda M, "Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis.", J Biol Chem, (277), pp.7487~7491 (2002)
22. Sun Z, "NF-kappaB activation and inhibition: a review", Shock, (18), pp.99~106 (2002)
23. van den Berg R, "Transcription factor NF-kappaB as a potential biomarker for oxidative stress.", Br J Nutr, 86(1), pp.S121~S127 (2001)
24. Bowie A, "Oxidative stress and nuclear factor- kappa B activation: a reassessment of the evidence in the light of recent discoveries", Biochem Pharmacol, 59(1), pp.13~23 (2000)
25. Ouchi N, "Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway.", Circulation, (102), pp.1296~1301 (2000)
26. Steinberg HO, "Obesity", insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance, 1996, pp.(97), 2601~2610
27. Parissis JT, "Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension. Correlations with plasma endothelin-1.", Int J Cardiol, (83), pp.13~21 (2002)
28. Tooke JE, "Endotheliopathy precedes type 2 diabetes.", Diabetes Care, (21), pp.2047~2049 (1998)
29. Visser M, "Elevated C-reactive protein levels in overweight and obese adults.", JAMA, (282), pp.2131~2135 (1999)
30. Tamakoshi K, "The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy referce range, a systemic low-grade inflammatory state.", Int J Obes Relat Metab Disord, (27), pp.443~449 (2003)
31. Zwaka TP, "C-reactive protein- mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis.", Circulation, (103), pp.1194~1197 (2001)
32. Greenberg AS, "Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes.", Eur J Clin Inves, 32(3), pp.S24~S34 (2002)
33. Lang CH, "Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output.", Endocrinology., (130), pp.43~52 (1992)
34. Katsuki A, "Serum levels of tumor necrosis factor-alpha are increased in obese patients with non insulin-dependent diabetes mellitus.", J Clin Endocrinol Metab, (83), pp.859~862 (1998)
35. Pouliot MC, "Associations between regional body fat distribution, fasting plasma free fatty acid levels and glucose tolerance in premenopausal women.", Int J Obes, (14), pp.293~302 (1990)
36. Terry RB, "Contributions of regional adipose tissue depots to plasma lipoprotein concentrations in overweight men and women:possible protective effects of thigh fat.", Metabolism, (40), pp.733~740 (1991)
37. Randle PJ, "The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus", Ann N Y Acad Sci, (131), pp.324~333 (1965)
38. Shankar SS, "FFAs: do they play a role in vascular disease in the insulin resistance syndrome?", Curr Diab Rep, 5(1), pp.30~35 (2005)
39. Evans JL, "Oxidative stress and stress-activated signaling pathway: a unifying hypothesis of type 2 diabetes", Endocr Rev, (23), pp.599~622 (2002)
40. Sonnenberg GE, "A novel pathway to the manifestations of Metabolic syndrome.", Obes Res, (12), pp.180~186 (2004)
41. Dagenais GR, "Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases", Curr Cardiol Rep, 2(4), pp.293~299 (2000)
42. Ford ES, "The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey.", Diabetes, 52(9), pp.2346~2352 (2003)
43. Chen J, "Serum antioxidant vitamins and blood pressure in the United States population.", Hypertension, 40(6), pp.810~816 (2002)
44. Diaz MN, "Antioxidants and atherosclerotic heart disease", N Engl J Med, 337(6), pp.408~416 (1997)
45. Som S, "Ascorbic acid metabolism in diabetes mellitus.", Metabolism, 30(6), pp.572~577 (1981)
46. Cunningham JJ, "Vitamin C: an aldose reductase inhibitor that normalizes erythrocyte sorbitol in insulin-dependent diabetes mellitus.", J Am Coll Nutr, 13(4), pp.344~350 (1994)
47. Vincent TE, "Inhibition of aldose reductase in human erythrocytes by vitamin C", Diabetes Res Clin Pract, 43(1), pp.1~8 (1999)
48. Hirashima O, "Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species.", J Am Coll Cardiol, 35(7), pp.1860~1866 (2000)
49. Price KD, "Hyperglycemia-induced ascorbic acid deficiency promotes endothelial dysfunction and the development of atherosclerosis.", Atherosclerosis, 158(1), pp.1~12 (2001)
50. Beckman JA, "Ascorbate restores endothelium-dependent vasodilation impaired by acute hyperglycemia in humans.", Circulation, 103(12), pp.1618~1623 (2001)
51. Natali A, "Effect of vitamin C on forearm blood flow and glucose metabolism in essential hypertension", Arterioscler Thromb Vasc Biol, 20(11), pp.2401~2406 (2000)
52. Bates CJ, "Does vitamin C reduce blood pressure? Results of a large study of people aged 65 or older.", J Hypertens, 16(7), pp.925~932 (1998)
53. Ness AR, "Vitamin C and blood pressure--an overview", J Hum Hypertens, 11(6), pp.343~350 (1997)
54. Kushi LH, "Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women.", N Engl J Med, 334(18), pp.1156~1162 (1996)
55. Rimm EB, "Vitamin E consumption and the risk of coronary heart disease in men", N Engl J Med, 328(20), pp.1450~1456 (1993)
56. Osganian SK,, "Vitamin C and risk of coronary heart disease in women.", J Am Coll Cardiol, 42(2), pp.246~252 (2003)
57. Knekt P, "Antioxidant vitamins and coronary heart disease risk: a pooled analysis of 9 cohorts.", Am J Clin Nutr, 80(6), pp.1508~1520 (2004)
58. Lawlor DA, "Vitamin C is not associated with coronary heart disease risk once life course socioeconomic position is taken into account: prospective findings from the British Women’s Heart and Health Study", Heart, 91(8), pp.1086~1087 (2005)
59. Kris-Etherton PM, "Steinberg D, Witztum JL; Nutrition Committee of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Antioxidant vitamin supplements and cardiovascular disease", Circulation, 110(5), pp.637~641 (2004)
60. Pezeshk A, "Vitamin E, membrane fluidity, and blood pressure in hypertensive and normotensive rats.", Life Sci, 67(15), pp.1881~1889 (2000)
61. Palumbo G, "Effects of vitamin E on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study.", Am J Hypertens, 13(5 Pt 1), pp.564~567 (2000)
62. Manning PJ, "Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects.", Diabetes Care, 27(9), pp.2166~2171 (2004)
63. Paolisso G, "Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients.", Diabetes Care, 16(11), pp.1433~1437 (1993)
64. Stampfer MJ, "Vitamin E consumption and the risk of coronary disease in women", N Engl J Med, 328(20), pp.1444~1449 (1993)
65. Virtamo J, "Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease.", Arch Intern Med, 158(6), pp.668~675 (1998)
66. Leppala JM, "Vitamin E and beta carotene supplementation in high risk for stroke: a subgroup analysis of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.", Arch Neuro, 57(10), pp.1503~1509 (2000)
67. Yochum LA, "Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women.", Am J Clin Nutr, 72(2), pp.476~483 (2000)
68. de Gaetano G, "Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project", Lancet, 357(9250), pp.89~95 (2001)
69. Stephens NG, "Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).", Lancet, 347(9004), pp.781~786 (1996)
70. Yusuf S, "Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342(3), pp.154~160 (2000)
71. Hodis HN, "Alpha-tocopherol supplementation in healthy indivi duals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS).", Circulation, 106(12), pp.1453~1459 (2002)
72. Miller ER 3rd, "Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality", Ann Intern Med, 142(1), pp.37~46 (2005)
73. Hennekens CH, "Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.", N Engl J Med, 334(18), pp.1145~1149 (1996)
74. "The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha- Tocopherol, Beta Carotene Cancer Prevention Study Group.", N Engl J Med, 330(15), pp.1029~1035 (1994)
75. Traulsen H, "Selenoprotein P protects low-density lipoprotein against oxidation.", Free Radic Res, 38(2), pp.123~128 (2004)
76. Stapleton SR, "Selenium: an insulin-mimetic.", Cell Mol Life Sci, 57(13-14), pp.1874~1879 (2000)
77. Salonen JT, "Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study.", Lancet, 2(8291), pp.175~179 (1982)
78. Suadicani P, "Serum selenium concentration and risk of ischaemic heart disease in a prospective cohort study of 3000 males.", Atherosclerosis, 96(1), pp.33~42 (1992)
79. Rayman MP, "The importance of selenium to human health.", Lancet, 356(9225), pp.233~241 (2000)
80. Galley HF, "Combination oral antioxidant supplementation reduces blood pressure.", Clin Sci (Lond), 92(4), pp.361~365 (1997)
81. Miller ER 3rd, "The effect of antioxidant vitamin supplementation on traditional cardiovascular risk factors", J Cardiovasc Risk, 4(1), pp.19~24 (1997)
82. Brown BG, "Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease", N Engl J Med, 345(22), pp.1583~1592 (2001)
83. Waters DD, "Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial", JAMA, 288(19), pp.2432~2440 (2002)
84. Heart Protection Study Collaborative Group., "MRC", BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomized placebo- controlled trial., 2002, pp.360(9326), 23~33

관련 논문AI추천